UB Paderborn / Katalog / Suche / in CDI

Some remaining challenges regarding multiple endpoints in clinical trials

Statistics in medicine, 2017-12, Vol.36 (28), p.4441-4445

Snapinn, Steven

2017

Volltextzugriff (PDF)

A shrinkage estimator for subgroup analysis without the exchangeability assumption

Journal of biopharmaceutical statistics, 2021-11, Vol.31 (6), p.723-735

Snapinn, Steven

2021

Volltextzugriff (PDF)

Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator

The American statistician, 2005-11, Vol.59 (4), p.301-307

2005

Volltextzugriff (PDF)

Comparison of Sample Size Requirements of Randomized and Historically Controlled Trials Based on Calibrated Error Rates

Statistics in biopharmaceutical research, 2023-01, Vol.15 (1), p.69-73

2023

Volltextzugriff (PDF)

Assessment of futility in clinical trials

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2006-10, Vol.5 (4), p.273-281

2006

Volltextzugriff (PDF)

Treatment effect measures under nonproportional hazards

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2023-01, Vol.22 (1), p.181-193

2023

Volltextzugriff (PDF)

Comment on "Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group": The Test Statistic Should Estimate Some Reasonable Measure of Treatment Benefit

Statistics in biopharmaceutical research, 2023-04, Vol.15 (2), p.297-299

2023

Volltextzugriff (PDF)

Proportion of treatment effect (PTE) explained by a surrogate marker

Statistics in medicine, 2003-11, Vol.22 (22), p.3449-3459

2003

Volltextzugriff (PDF)

On the clinical meaningfulness of a treatment's effect on a time-to-event variable

Statistics in medicine, 2011-08, Vol.30 (19), p.2341-2348

2011

Volltextzugriff (PDF)

Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials

Statistics in medicine, 2008-02, Vol.27 (3), p.382-391

2008

Volltextzugriff (PDF)

Comment on "The Role of p-Values in Judging the Strength of Evidence and Realistic Replication Expectations"

Statistics in biopharmaceutical research, 2021-02, Vol.13 (1), p.40-42

2021

Volltextzugriff (PDF)

Controlling the type 1 error rate in non-inferiority trials

Statistics in medicine, 2008-02, Vol.27 (3), p.371-381

2008

Volltextzugriff (PDF)

Pure and Hybrid Causal Effects on Variables Associated with an Incident Event

Journal of biopharmaceutical statistics, 2013-07, Vol.23 (4), p.719-729

2013

Volltextzugriff (PDF)

Indirect comparisons in the comparative efficacy and non-inferiority settings

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2011-09, Vol.10 (5), p.420-426

2011

Volltextzugriff (PDF)

Analysis of multiple endpoints in clinical trials: it's time for the designations of primary, secondary and tertiary to go

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2011-01, Vol.10 (1), p.1-2

2011

Volltextzugriff (PDF)

Survival Analysis with Uncertain Endpoints

Biometrics, 1998-03, Vol.54 (1), p.209-218

Snapinn, Steven M.

1998

Volltextzugriff (PDF)

Predicting analysis time in event-driven clinical trials with event-reporting lag

Statistics in medicine, 2012-04, Vol.31 (9), p.801-811

2012

Volltextzugriff (PDF)

On Errors in Stratified Randomization

Statistics in biopharmaceutical research, 2017-04, Vol.9 (2), p.225-233

2017

Volltextzugriff (PDF)

Nonproportional Hazards and the Power of Sequential Trials

Statistics in biopharmaceutical research, 2009-02, Vol.1 (1), p.66-73

2009

Volltextzugriff (PDF)

Responder Analyses-A PhRMA Position Paper

Statistics in biopharmaceutical research, 2011-08, Vol.3 (3), p.476-487

2011

Volltextzugriff (PDF)

Calculation of Sample Size in Survival Trials: The Impact of Informative Noncompliance

Biometrics, 2004-09, Vol.60 (3), p.800-806

2004

Volltextzugriff (PDF)

Uncertainty in Clinical Endpoints: Information and Retrieval

Statistics in biopharmaceutical research, 2009-11, Vol.1 (4), p.362-365

2009

Volltextzugriff (PDF)

The role of the unblinded sponsor statistician

Statistics in medicine, 2004-05, Vol.23 (10), p.1531-1533

2004

Volltextzugriff (PDF)

A discriminant analysis extension to mixed models

Statistics in medicine, 1999-05, Vol.18 (10), p.1249-1260

1999

Volltextzugriff (PDF)

PISC Expert Team White Paper: Toward a Consistent Standard of Evidence When Evaluating the Efficacy of an Experimental Treatment From a Randomized, Active-Controlled Trial

Statistics in biopharmaceutical research, 2010-11, Vol.2 (4), p.522-531

2010

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Some remaining challenges regarding multiple endpoints in clinical trials

A shrinkage estimator for subgroup analysis without the exchangeability assumption

Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator

Comparison of Sample Size Requirements of Randomized and Historically Controlled Trials Based on Calibrated Error Rates

Assessment of futility in clinical trials

Treatment effect measures under nonproportional hazards

Comment on "Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group": The Test Statistic Should Estimate Some Reasonable Measure of Treatment Benefit

Proportion of treatment effect (PTE) explained by a surrogate marker

On the clinical meaningfulness of a treatment's effect on a time-to-event variable

Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials

Comment on "The Role of p-Values in Judging the Strength of Evidence and Realistic Replication Expectations"

Controlling the type 1 error rate in non-inferiority trials

Pure and Hybrid Causal Effects on Variables Associated with an Incident Event

Indirect comparisons in the comparative efficacy and non-inferiority settings

Analysis of multiple endpoints in clinical trials: it's time for the designations of primary, secondary and tertiary to go

Survival Analysis with Uncertain Endpoints

Predicting analysis time in event-driven clinical trials with event-reporting lag

On Errors in Stratified Randomization

Nonproportional Hazards and the Power of Sequential Trials

Responder Analyses-A PhRMA Position Paper

Calculation of Sample Size in Survival Trials: The Impact of Informative Noncompliance

Uncertainty in Clinical Endpoints: Information and Retrieval

The role of the unblinded sponsor statistician

A discriminant analysis extension to mixed models

PISC Expert Team White Paper: Toward a Consistent Standard of Evidence When Evaluating the Efficacy of an Experimental Treatment From a Randomized, Active-Controlled Trial

Aktive Filter

Suchergebnisse filtern